Abstract
Characterizing the functions of the many genes discovered by the sequencing projects is now the primary focus of genome-scale studies. Although sequence or structure-based comparisons are helping to generate hypotheses on the biochemical functions of many gene products, determining the in vivo role(s) for large sets of genes remains a critical objective. RNA interference (RNAi) offers a rapid way to gain a first look at loss-of-function phenotypes associated with specific genes. So far RNAi has been used to test the function of a third of the predicted genes in the Caenorhabditis elegans (C. elegans) genome, and it can be expected that a first pass survey of the entire genome will soon be completed. From the current body of work an initial estimate of the power and challenges of using RNAi for genome-wide analyses can be made. A comparison of results obtained from independent large-scale RNAi studies reveals that despite a high degree of congruence, no single study is likely to achieve a comprehensive RNAi-based phenotypic ”map“ of the C. elegans genome instead a more accurate picture will be assembled from a composite of independent results for the same genes. RNAi analysis, together with other functional genomic approaches such as expression profiling and protein interaction mapping, is transforming C. elegans into a premier model system for the development and integration of functional genomic approaches in a metazoan.
Keywords: Rnai-based functional genomics, Caenorhabditis elegans
Current Genomics
Title: RNAi-Based Functional Genomics in Caenorhabditis elegans
Volume: 3 Issue: 2
Author(s): F. Piano and K. Gunsalus
Affiliation:
Keywords: Rnai-based functional genomics, Caenorhabditis elegans
Abstract: Characterizing the functions of the many genes discovered by the sequencing projects is now the primary focus of genome-scale studies. Although sequence or structure-based comparisons are helping to generate hypotheses on the biochemical functions of many gene products, determining the in vivo role(s) for large sets of genes remains a critical objective. RNA interference (RNAi) offers a rapid way to gain a first look at loss-of-function phenotypes associated with specific genes. So far RNAi has been used to test the function of a third of the predicted genes in the Caenorhabditis elegans (C. elegans) genome, and it can be expected that a first pass survey of the entire genome will soon be completed. From the current body of work an initial estimate of the power and challenges of using RNAi for genome-wide analyses can be made. A comparison of results obtained from independent large-scale RNAi studies reveals that despite a high degree of congruence, no single study is likely to achieve a comprehensive RNAi-based phenotypic ”map“ of the C. elegans genome instead a more accurate picture will be assembled from a composite of independent results for the same genes. RNAi analysis, together with other functional genomic approaches such as expression profiling and protein interaction mapping, is transforming C. elegans into a premier model system for the development and integration of functional genomic approaches in a metazoan.
Export Options
About this article
Cite this article as:
Piano F. and Gunsalus K., RNAi-Based Functional Genomics in Caenorhabditis elegans, Current Genomics 2002; 3 (2) . https://dx.doi.org/10.2174/1389202024605224
DOI https://dx.doi.org/10.2174/1389202024605224 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acknowledgements to Contributors
Recent Patents on Inflammation & Allergy Drug Discovery Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design Recent Scientific Advances Towards the Development of Tendon Healing Strategies
Current Tissue Engineering (Discontinued) An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone
Cardiovascular & Hematological Disorders-Drug Targets Macrolides Allergy
Current Pharmaceutical Design Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Endothelial Dysfunction and Coronary Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets A Recent Overview on Dermatological Applications of Liposomes
Recent Patents on Nanotechnology Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets A Review of Polymeric Colloidal Nanogels in Transdermal Drug Delivery
Current Pharmaceutical Design Role of Deoxyribonucleoside Kinases and Deoxyribonucleotide Pool Alterations in Nucleoside Reverse Transcriptase Inhibitor Induced Mitochondrial Toxicity
Current Medicinal Chemistry - Anti-Infective Agents Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Current Diabetes Reviews Editorial [Hot Topic: New Potential Pharmaceutical Targets of Metabolic Syndrome (Executive Editors: Gianluca Iacobellis and Giuseppe Barbaro)]
Current Pharmaceutical Design Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders